AR053554A1 - Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos - Google Patents

Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Info

Publication number
AR053554A1
AR053554A1 ARP060100919A ARP060100919A AR053554A1 AR 053554 A1 AR053554 A1 AR 053554A1 AR P060100919 A ARP060100919 A AR P060100919A AR P060100919 A ARP060100919 A AR P060100919A AR 053554 A1 AR053554 A1 AR 053554A1
Authority
AR
Argentina
Prior art keywords
treatment
hyperproliferative disorders
pirimidine derivatives
pirimidine
derivatives
Prior art date
Application number
ARP060100919A
Other languages
English (en)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36624969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053554(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AR053554A1 publication Critical patent/AR053554A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Las composiciones farmacéuticas que contienen estos compuestos, y los métodos para usar estos compuestos en el tratamiento de enfermedades hiperproliferativas como el cáncer. Reivindicacion 1. Un compuesto de formula (1) en donde R1 representa H; R2 representa -NH2, L representa O; M es CH; n es 1; n' es 0, 1 o 2; G es metilo o trifluorometilo; G' es piridilo o pirimidilo; Y es fenilo, piridilo o pirimidilo; o una de sus sales farmacéuticamente aceptables.
ARP060100919A 2005-03-10 2006-03-10 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos AR053554A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66056105P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
AR053554A1 true AR053554A1 (es) 2007-05-09

Family

ID=36624969

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100919A AR053554A1 (es) 2005-03-10 2006-03-10 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Country Status (23)

Country Link
US (1) US20110098301A1 (es)
EP (1) EP1858882A1 (es)
JP (1) JP2008533042A (es)
KR (1) KR20080004488A (es)
CN (1) CN101151258A (es)
AR (1) AR053554A1 (es)
AU (1) AU2006223199A1 (es)
BR (1) BRPI0609022A2 (es)
CA (1) CA2601257A1 (es)
CR (1) CR9347A (es)
DO (1) DOP2006000061A (es)
EA (1) EA200701930A1 (es)
GT (1) GT200600105A (es)
IL (1) IL185498A0 (es)
MA (1) MA29377B1 (es)
MX (1) MX2007010102A (es)
NO (1) NO20074964L (es)
PE (1) PE20061067A1 (es)
TN (1) TNSN07322A1 (es)
TW (1) TW200724537A (es)
UY (1) UY29414A1 (es)
WO (1) WO2006099231A1 (es)
ZA (1) ZA200708591B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001477A4 (en) * 2006-03-20 2010-07-21 Bayer Healthcare Llc COMBINATION OF PACLITAXEL
CN101765591B (zh) * 2007-07-26 2013-11-27 诺华股份有限公司 用于治疗炎性或过敏性病症的嘧啶衍生物
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
CN103228274A (zh) 2010-10-01 2013-07-31 拜耳知识产权有限责任公司 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合
CN103270026A (zh) 2010-12-21 2013-08-28 诺瓦提斯公司 作为vps34抑制剂的联-杂芳基化合物
CN103492370B (zh) 2011-04-22 2016-10-26 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9638690B2 (en) 2014-11-07 2017-05-02 The University Of British Columbia Compounds and compositions for use as alkylating agent sensors and methods of use thereof
CA2975260A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA2993173C (en) 2015-07-24 2023-10-03 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
TWI609028B (zh) 2016-05-06 2017-12-21 財團法人工業技術研究院 共聚物與含其之樹脂組合物、封裝膜及封裝結構
CN111518078B (zh) * 2020-05-30 2021-02-26 南方医科大学 一种含氨基吡啶的嘧啶类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089480B2 (ja) * 1990-09-20 2000-09-18 ソニー株式会社 フリットシール装置
MXPA04007196A (es) * 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
JP4948173B2 (ja) * 2003-10-10 2012-06-06 ニツポネツクス・インコーポレーテツド 過剰増殖性疾患治療用ピリミジン誘導体

Also Published As

Publication number Publication date
UY29414A1 (es) 2006-10-02
AU2006223199A1 (en) 2006-09-21
ZA200708591B (en) 2009-01-28
BRPI0609022A2 (pt) 2010-01-12
CA2601257A1 (en) 2006-09-21
IL185498A0 (en) 2008-01-06
TNSN07322A1 (en) 2008-12-31
EA200701930A1 (ru) 2008-02-28
CR9347A (es) 2007-12-17
KR20080004488A (ko) 2008-01-09
MA29377B1 (fr) 2008-04-01
MX2007010102A (es) 2007-10-12
DOP2006000061A (es) 2006-09-30
US20110098301A1 (en) 2011-04-28
EP1858882A1 (en) 2007-11-28
WO2006099231A1 (en) 2006-09-21
TW200724537A (en) 2007-07-01
CN101151258A (zh) 2008-03-26
GT200600105A (es) 2007-02-14
NO20074964L (no) 2007-12-06
PE20061067A1 (es) 2006-11-30
JP2008533042A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PA8591701A1 (es) Derivados de pirrolopirimidina
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
CR9954A (es) Derivados de pirazina
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR049577A1 (es) Derivados de hidantoina, procesos para su preparacion, composiciones y su uso
AR066972A1 (es) Derivados azapeptidicos
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
UY28333A1 (es) Inhibidores de caspasa y sus usos.
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal